TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00431418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT01036802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04585997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: Mepolizumab 100mg subcutaneous injection monthly for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
Study: NCT02644746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo needle
Description: Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
Study: NCT00909870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft(R)
Description: Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
Study: NCT03662412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral solution of sirolimus, 2mg, once a day.
Study: NCT02245711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Study: NCT01107548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic detection of vascular risk factors and subsequent evidence-based treatment
Study: NCT02879058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative contact ultrasonography
Description: In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
Study: NCT01470716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
Study: NCT01192178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT™ DISKUS™ 100 mcg BID
Description: FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR™ DISKUS™ 100/50 mcg BID
Description: ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
Study: NCT04482634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote controlled exercise
Description: Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
Study: NCT01579214

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cellular Phone Text Messages
Description: Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
Study: NCT02450643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test extensively hydrolyzed formula
Description: extensively hydrolyzed formula made with a new enzyme

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test extensively hydrolyzed formula
Description: extensively hydrolyzed formula made with a new enzyme

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control extensively hydrolyzed formula
Description: commercially available extensively hydrolyzed formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control extensively hydrolyzed formula
Description: commercially available extensively hydrolyzed formula
Study: NCT03342066

Intervention type: DIAGNOSTIC_TEST
Intervention: reproducability of caries risk assessment
Description: reproducability of caries risk assessment CAMBRA verses cariogram

Intervention type: DIAGNOSTIC_TEST
Intervention: reproducability of caries risk assessment
Description: reproducability of caries risk assessment CAMBRA verses cariogram
Study: NCT03002402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT-I
Description: Internet-based cognitive-behavioral treatment for insomnia
Study: NCT02554396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-100
Description: ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline ophthalmic solution
Study: NCT02239211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT1023
Description: IV (in the vein) Investigational Medicinal Product (IMP)
Study: NCT01141556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selenase
Description: After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenase
Description: After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
Study: NCT01467882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Powder and solution for solution for injection
Study: NCT01277861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
Study: NCT01694680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein-enriched-egg beverage (NWT-02)
Description: Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: color-, taste- and energy-matched powder without enriched egg-yolk
Study: NCT04025424

Intervention type: GENETIC
Intervention: Genetic tests of the available tumor and plasma samples
Description: Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Study: NCT05880745

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nine-Hole Peg Test (NHPT)
Description: Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nine-Hole Peg Test (NHPT)
Description: Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
Study: NCT04487704

Intervention type: OTHER
Group type: OTHER
Intervention: camrelizumab
Description: camrelizumab 200 mg, intravenous infusion (no need for prophylactic administration), no less than 30 min ，No more than 60 min, one cycle every 2 weeks (14 days) or one cycle every 3 weeks (21 days). Try to complete the administration before the ECG
Study: NCT04325360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cathodal Transcranial Direct Current Stimulation
Description: 20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation
Description: Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
Study: NCT04025424

Intervention type: GENETIC
Intervention: Genetic tests of the available tumor and plasma samples
Description: Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned

Intervention type: GENETIC
Intervention: Genetic tests of the available tumor and plasma samples
Description: Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned

Intervention type: GENETIC
Intervention: Genetic tests of the available tumor and plasma samples
Description: Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned

Intervention type: GENETIC
Intervention: Genetic tests of the available tumor and plasma samples
Description: Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Study: NCT03077217

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin
Description: The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
Study: NCT01349595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area).
Study: NCT04249024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal flap surgery
Description: The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
Study: NCT02352194

Intervention type: OTHER
Intervention: Rehabilitation
Description: Physiotherapy and physical activity
Study: NCT03133676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KA34
Description: 50 µg - 400 µg intra-articular injection (single or multiple doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 µg - 400 µg intra-articular injection (single or multiple doses)
Study: NCT02629783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychomotor therapy
Description: 1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid injection
Description: At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
Study: NCT03517904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS-guided angioplasty
Description: Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided angioplasty
Description: Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
Study: NCT01982864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance...).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD).
Study: NCT02823119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-hysteroscopy
Description: Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Office Hysteroscopy
Description: . Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
Study: NCT00851487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral Amoxicillin 15 mg/kg/dose 8 hourly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was similar in colour, consistency and volume as oral amoxicillin
Study: NCT02797431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR\>2.5 or platelet count \< 35,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR\>2.5 or platelet count \< 35,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Study: NCT04428268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Phosphate Tablets
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate Tablets
Description: Orally administered
Study: NCT01315210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Ribose Powder
Description: 5 g TID for 12 Weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 5 g TID for 12 Weeks
Study: NCT02734576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Sinus Stenting with the Precise Pro Stent
Description: Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
Study: NCT02414061

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein (Arla Foods Ingredients Group)
Description: 20 g whey protein isolate added to breakfast meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast meal
Description: Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast meal
Description: Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
Study: NCT03028441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: Measles-vectored Chikungunya vaccine